Chugai Plans Japan Launch Of Combo Breast-Cancer Drug In 2013
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical says it expects to apply for Japan approval next year for its T-DMI1 (trasfuzumab/emtansine) antibody drug conjugate for HER2-positive breast cancer.